Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA

[11] Schulman KL(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-986

[12] Patel MR(2019)Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants J Med Econ 22 751-961

[13] Mahaffey KW(2016)Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin Thromb Haemost 116 975-2503

[14] Garg J(2017)Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting J Med Econ 20 952-1776

[15] Granger CB(2017)Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis Stroke 48 2494-972

[16] Alexander JH(2019)Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients Curr Med Res Opin 35 1769-undefined

[17] McMurray JJV(2015)Incremental health care burden of bleeding among patients with venous thromboembolism in the United States J Manag Care Spec Pharm 21 965-undefined

[18] Giugliano RP(undefined)undefined undefined undefined undefined-undefined

[19] Ruff CT(undefined)undefined undefined undefined undefined-undefined

[20] Braunwald E(undefined)undefined undefined undefined undefined-undefined

[11] Schulman KL(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-986

[12] Patel MR(2019)Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants J Med Econ 22 751-961

[13] Mahaffey KW(2016)Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin Thromb Haemost 116 975-2503

[14] Garg J(2017)Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting J Med Econ 20 952-1776

[15] Granger CB(2017)Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis Stroke 48 2494-972

[16] Alexander JH(2019)Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients Curr Med Res Opin 35 1769-undefined

[17] McMurray JJV(2015)Incremental health care burden of bleeding among patients with venous thromboembolism in the United States J Manag Care Spec Pharm 21 965-undefined

[18] Giugliano RP(undefined)undefined undefined undefined undefined-undefined

[19] Ruff CT(undefined)undefined undefined undefined undefined-undefined

[20] Braunwald E(undefined)undefined undefined undefined undefined-undefined